Southeast Asia-focused venture capital firm SeaX Ventures has invested in the seed funding round of U.S.-based biotech startup RyboDyn, which raised $10 million.
This funding aims to propel RyboDyn's innovative AI-driven platform, which targets the undiscovered "dark proteome" to identify novel cancer therapeutic targets from patient tumor samples.
Unlocking Hidden Cancer Targets with AI and Proteomics
RyboDyn integrates non-canonical RNA analysis, proteomics, and artificial intelligence to detect and validate cryptic proteins invisible to traditional sequencing methods.
The investment builds on SeaX Ventures' prior role as a co-lead investor in RyboDyn's pre-seed round, highlighting continued confidence in the startup’s research approach.
RyboDyn has analyzed over 1,000 patient tumor samples across multiple cancer types, uncovering millions of RNA sequences and tens of thousands of previously uncharacterized proteins, forming a proprietary dataset that enables repeatable discoveries.
SeaX Ventures, with offices in Bangkok and Silicon Valley, specializes in deep-tech investments across biotech, AI, and energy, leveraging Southeast Asian corporate networks for portfolio growth.
This latest round will advance RyboDyn's early-stage programs, including antibody-drug conjugates, toward clinical development.
By compiling a proprietary dataset, RyboDyn enables scalable discovery across multiple cancer types, strengthening its potential impact on precision oncology.
Future Implications for Oncology Innovation
Experts anticipate this funding could accelerate first-in-class treatments targeting the dark proteome, addressing unmet needs in cancer therapeutics.
As cancer remains a leading global health challenge, initiatives like RyboDyn's underscore AI's growing role in drug discovery and personalized medicine.
With this momentum, SeaX Ventures positions itself as a key player in fostering exponential technologies that expand from the U.S. into Southeast Asia and beyond.
Andrew Lee
